News

Video

ARVO 2024: Impact of switching when using an aflibercept biosimilar

SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."

At this year's ARVO meeting, SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

SriniVas R Sadda, MD:

Hi, I'm Vas Sadda, professor of ophthalmology at UCLA and at the Doheny Eye Institute. I'm here at ARVO 2024. And I was able to give a presentation here, paper presentation, on what is the impact of switching when using an aflibercept biosimilar. Biosimilars are a big deal now because they potentially could provide a more affordable way of providing anti-VEGF therapy for patients, and we have many patients on anti-VEGF therapy already. And we have a couple of approved biosimilars on the market for, at least for ranibizumab. And the question was, "Is it okay to take in a patient who on existing therapy and switch them to a biosimilar once it's available?" And that's what we evaluated in this study of SB15, and the aflibercept, which is an aflibercept biosimilar in this trial. What we show them, what we demonstrated was that you can switch and still have exactly the same visual outcomes, anatomic outcomes for patients. So that I think gives us good evidence and confidence to do this in clinical practice. Now, I do also want to just take a brief moment to highlight some of the other work we've been doing. I've been very fortunate working at the Doheny Eye Institute to have a very big research group and a number of wonderful collaborators. And we have a whole host of different posters and presentations and paper presentation that we've been giving here at ARVO highlighting from a number of different areas. I want to highlight in particular, 1 example of some new work, I think, what I think is very groundbreaking work in the development of adaptive optics based fluorescence lifetime imaging ophthalmoscopy. This is work that is being led by my colleague, Yuhua Zhang, we've collaborated on this, and it actually is able to give us imaging of essentially the molecular or metabolic level, at least of individual RP cells in the eye, which I think is going to be pretty spectacular in this new era of molecular type therapeutics. I've also done a lot of work and presenting here on AI-based algorithms for analyzing a variety of different imaging studies in ophthalmology, as well as a whole host of work related to new biomarkers that we've identified in the context of AMD. So it's been a great meeting, and I'm really looking forward to the next ARVO after this.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.